Publications:

---

[Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma 
with COX7A2L-ALK Fusion: A Case Report and Literature Review].

Zhongguo Fei Ai Za Zhi = Chinese Journal Of Lung Cancer

Yuan, Jiao J; Pan, Ruili R; Zhong, Wei W; Wang, Mengzhao M

Publication Date: 2023-04-20

Variant appearance in text: ALK: T1151K

PubMed Link: 37183647

Variant Present in the following documents:

• zgfazz-26-4-319.pdf

View BVdb publication page

---

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report.

Diagnostics (Basel, Switzerland)

Catino, Annamaria A; Lacalamita, Rosanna R; De Summa, Simona S; Pesola, Francesco F; Tommasi, Stefania S; Galetta, Domenico D

Publication Date: 2022-03-11

Variant appearance in text: ALK: 3452C>A; T1151K

PubMed Link: 35328235

Variant Present in the following documents:

• Main text
• diagnostics-12-00682.pdf

View BVdb publication page

---

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer Science

Koga, Takamasa T; Suda, Kenichi K; Mitsudomi, Tetsuya T

Publication Date: 2022-03

Variant appearance in text: ALK: T1151K

PubMed Link: 34997674

Variant Present in the following documents:

• CAS-113-815-s001.pdf
• CAS-113-815.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: T1151K

PubMed Link: 34885113

Variant Present in the following documents:

• Main text
• cancers-13-06003.pdf

View BVdb publication page

---

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers

Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD

Publication Date: 2021-11-29

Variant appearance in text: ALK: T1151K

PubMed Link: 34885113

Variant Present in the following documents:

• Main text
• cancers-13-06003.pdf

View BVdb publication page

---

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology

Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F

Publication Date: 2021

Variant appearance in text: ALK: T1151K

PubMed Link: 34660278

Variant Present in the following documents:

• Main text
• fonc-11-713530.pdf

View BVdb publication page

---

Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020.

Jto Clinical And Research Reports

Ou, Sai-Hong Ignatius SI; Zhu, Viola W VW; Nagasaka, Misako M

Publication Date: 2020-03

Variant appearance in text: ALK: T1151K

PubMed Link: 34589917

Variant Present in the following documents:

• main.pdf

View BVdb publication page

---

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.

Translational Lung Cancer Research

Christopoulos, Petros P; Dietz, Steffen S; Angeles, Arlou K AK; Rheinheimer, Stephan S; Kazdal, Daniel D; Volckmar, Anna-Lena AL; Janke, Florian F; Endris, Volker V; Meister, Michael M; Kriegsmann, Mark M; Zemojtel, Thomasz T; Reck, Martin M; Stenzinger, Albrecht A; Thomas, Michael M; Sültmann, Holger H

Publication Date: 2021-05

Variant appearance in text: ALK: T1151K

PubMed Link: 34164264

Variant Present in the following documents:

• tlcr-10-05-2118-supplementary.pdf

View BVdb publication page

---

Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling.

Oncotargets And Therapy

Yang, Ping P; Cao, Ran R; Bao, Hua H; Wu, Xue X; Yang, Lingling L; Zhu, Dongqin D; Zhang, Lu L; Peng, Liming L; Cai, Yuefei Y; Zhang, Weijun W; Shao, Yang Y

Publication Date: 2021

Variant appearance in text: ALK: T1151K

PubMed Link: 33790576

Variant Present in the following documents:

• ott-14-2131.pdf

View BVdb publication page

---

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Nature Communications

Mizuta, Hayato H; Okada, Koutaroh K; Araki, Mitsugu M; Adachi, Jun J; Takemoto, Ai A; Kutkowska, Justyna J; Maruyama, Kohei K; Yanagitani, Noriko N; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Friboulet, Luc L; Katayama, Kazuhiro K; Ma, Biao B; Sasakura, Yoko Y; Sagae, Yukari Y; Kukimoto-Niino, Mutsuko M; Shirouzu, Mikako M; Takagi, Satoshi S; Simizu, Siro S; Nishio, Makoto M; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2021-02-24

Variant appearance in text: ALK: T1151K

PubMed Link: 33627640

Variant Present in the following documents:

• Main text
• 41467_2021_21396_MOESM1_ESM.pdf
• 41467_2021_Article_21396.pdf

View BVdb publication page

---

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.

Ebiomedicine

Dietz, Steffen S; Christopoulos, Petros P; Yuan, Zhao Z; Angeles, Arlou Kristina AK; Gu, Lisa L; Volckmar, Anna-Lena AL; Ogrodnik, Simon J SJ; Janke, Florian F; Fratte, Chiara Dalle CD; Zemojtel, Tomasz T; Schneider, Marc A MA; Kazdal, Daniel D; Endris, Volker V; Meister, Michael M; Muley, Thomas T; Cecchin, Erika E; Reck, Martin M; Schlesner, Matthias M; Thomas, Michael M; Stenzinger, Albrecht A; Sültmann, Holger H

Publication Date: 2020-12

Variant appearance in text: ALK: 3452C>A; Thr1151Lys

PubMed Link: 33161228

Variant Present in the following documents:

• mmc1.pdf

View BVdb publication page

---

Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and Acquired SLCO2A1-ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report.

Oncotargets And Therapy

Cai, Chengzhi C; Long, Yaling Y; Li, Yanying Y; Huang, Meijuan M

Publication Date: 2020

Variant appearance in text: ALK: T1151K

PubMed Link: 32903930

Variant Present in the following documents:

• ott-13-8313.pdf

View BVdb publication page

---

Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors.

Oncotarget

Tuna, Musaffe M; Amos, Christopher I CI; Mills, Gordon B GB

Publication Date: 2019-03-12

Variant appearance in text: ALK: T1151K

PubMed Link: 31007851

Variant Present in the following documents:

• oncotarget-10-2095-s001.pdf

View BVdb publication page

---

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Ebiomedicine

Okada, Koutaroh K; Araki, Mitsugu M; Sakashita, Takuya T; Ma, Biao B; Kanada, Ryo R; Yanagitani, Noriko N; Horiike, Atsushi A; Koike, Sumie S; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Maemondo, Makoto M; Nishio, Makoto M; Ishikawa, Takeshi T; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R

Publication Date: 2019-03

Variant appearance in text: ALK: T1151K

PubMed Link: 30662002

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation.

Lung Cancer (Auckland, N.Z.)

Zhu, Viola W VW; Schrock, Alexa B AB; Bosemani, Thangavijayan T; Benn, Bryan S BS; Ali, Siraj M SM; Ou, Sai-Hong Ignatius SI

Publication Date: 2018

Variant appearance in text: ALK: T1151K

PubMed Link: 30519133

Variant Present in the following documents:

• Main text
• lctt-9-111.pdf

View BVdb publication page

---

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.

Cancers

Schrank, Zachary Z; Chhabra, Gagan G; Lin, Leo L; Iderzorig, Tsatsral T; Osude, Chike C; Khan, Nabiha N; Kuckovic, Adijan A; Singh, Sanjana S; Miller, Rachel J RJ; Puri, Neelu N

Publication Date: 2018-07-04

Variant appearance in text: ALK: T1151K

PubMed Link: 29973561

Variant Present in the following documents:

• Main text
• cancers-10-00224.pdf

View BVdb publication page

---

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.

Oncotarget

Amin, Amit Dipak AD; Li, Lingxiao L; Rajan, Soumya S SS; Gokhale, Vijay V; Groysman, Matthew J MJ; Pongtornpipat, Praechompoo P; Tapia, Edgar O EO; Wang, Mengdie M; Schatz, Jonathan H JH

Publication Date: 2016-04-26

Variant appearance in text: ALK: T1151K

PubMed Link: 27009859

Variant Present in the following documents:

• Main text
• oncotarget-07-23715.pdf

View BVdb publication page

---

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Oncotarget

Mologni, Luca L; Ceccon, Monica M; Pirola, Alessandra A; Chiriano, Gianpaolo G; Piazza, Rocco R; Scapozza, Leonardo L; Gambacorti-Passerini, Carlo C

Publication Date: 2015-03-20

Variant appearance in text: ALK: T1151K

PubMed Link: 25749034

Variant Present in the following documents:

• oncotarget-06-5720-s001.pdf

View BVdb publication page

---

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Chemical Biology & Drug Design

Zhang, Sen S; Wang, Frank F; Keats, Jeffrey J; Zhu, Xiaotian X; Ning, Yaoyu Y; Wardwell, Scott D SD; Moran, Lauren L; Mohemmad, Qurish K QK; Anjum, Rana R; Wang, Yihan Y; Narasimhan, Narayana I NI; Dalgarno, David D; Shakespeare, William C WC; Miret, Juan J JJ; Clackson, Tim T; Rivera, Victor M VM

Publication Date: 2011-12

Variant appearance in text: ALK: T1151K

PubMed Link: 22034911

Variant Present in the following documents:

• Main text
• cbdd0078-0999.pdf

View BVdb publication page

---